Patients with advanced GC who have undergone HER‐2 overexpression as a result of gene amplification in their tumor cells have been demonstrated to have an elevated chance of survival when treated with the monoclonal antibody trastuzumab, which targets HER‐2. This evidence concerns the gene ERBB2 and gastric cancer.